BOSTON , Sept. 19, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the appointment of Alison O'Neill , M.
D., as Chief Medical Officer. "I am thrilled to welcome Alison, an accomplished industry leader, to HotSpot," said Jonathan Montagu , Co-Founder and Chief Executive Officer of HotSpot Therapeutics.
"Her extensive biopharmaceutical experience and proven track record in clinical development strategy and execution will be invaluable as we advance our pipeline of innovative allosteric drug candidates. We look forward to her insights and leadership as we work to bring novel therapies to patients." Dr.
O'Neill joins HotSpot from Surface Oncology, Inc., where she served as Chief Medical Officer, overseeing the clinical development of Surface's pipeline of investigative immune-oncology agents. She has over 15 years of experience in the biopharma industry, working in small biotechnology companies, as well as large pharmaceutical companies, including Radius Health, Inc.
, Synta Pharmaceuticals, Inc., and Sanofi, to bring novel cancer agents into the clinic in order to benefit patients. During the first portion of her career, Dr.
O'Neill was an academic neuro-oncologist, caring for patients with cancers affecting the brain and nervous system, as well as conducting clinical research and t.